CanSinoBIO rebrands to reflect commitment to life sciences research
This is the first major brand refresh of CanSinoBIO since its inception in 2009
This is the first major brand refresh of CanSinoBIO since its inception in 2009
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
The goal for the project is the identification and optimization of anti-viral compounds.
Subscribe To Our Newsletter & Stay Updated